Table 4 Sensitivity of tumour markers according to tumour type
From: Evaluation of two strategies for the interpretation of tumour markers in pleural effusions
Single cut-offa | Ratio F/Sb | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
Tumour type | CA15-3 | CEA | CA19-9 | CA72-4 | All TM | CA15-3 | CEA | CA19-9 | CA72-4 | All TM |
Lung cancer (n = 46) | 43.5% (20/46) | 43.5% (20/46) | 28.3% (13/46) | 30.4% (14/46) | 71.7% (33/46) | 36.9% (17/46) | 78.2% (36/46) | 41.3% (19/46) | 39.1% (18/46) | 89.1% (41/46) |
CUP (n = 18) | 50.0% (9/18) | 72.2% (13/18) | 33.3% (6/18) | 55,5% (10/18) | 94.4% (17/18) | 55.5% (10/18) | 72.2% (13/18) | 50.0% (9/18) | 55.5% (10/18) | 88.9% (16/18) |
Mesothelioma (n = 15) | 6.7% (1/15) | 0.0% (0/15) | 0.0% (0/15) | 0.0% (0/15) | 6.7% (1/15) | 46.7% (7/15) | 0.0% (0/15) | 6.7% (1/15) | 0.0% (0/15) | 46.7% (7/15) |
Breast cancer (n = 13) | 61.5% (8/13) | 7.7% (1/13) | 0.0% (0/13) | 38.5% (5/13) | 92.3% (12/13) | 53.8% (7/13) | 61.5% (8/13) | 0% (0/13) | 38.5% (5/13) | 84.6% (11/13) |
Lymphoma (n = 9) | 0.0% (0/9) | 0.0% (0/9) | 0.0% (0/9) | 0.0% (0/9) | 0.0% (0/9) | 0% (0/9) | 0% (0/9) | 0% (0/9) | 0% (0/9) | 0% (0/9) |
Bladder cancer (n = 5) | 100% (5/5) | 60.0% (3/5) | 0.0% (0/5) | 40.0% (2/5) | 100% (5/5) | 60.0% (3/5) | 80.0% (4/5) | 40.0% (2/5) | 40.0% (2/5) | 100% (5/5) |
Ovarian cancer /PSPC* (n = 3) | 66.6% (2/3) | 33.3% (1/3) | 33.3% (1/3) | 66.6% (2/3) | 100% (3/3) | 66.6% (2/3) | 33.3% (1/3) | 33.3% (1/3) | 66.6% (2/3) | 100% (3/3) |
Stomach cancer (n = 3) | 33.3% (1/3) | 100% (3/3) | 100% (3/3) | 100% (3/3) | 100% (3/3) | 33.3% (1/3) | 66.6% (2/3) | 66.6% (2/3) | 100% (3/3) | 100% (3/3) |
Cholangiocarcinoma (n = 2) | 0.0% (0/2) | 50% (1/2) | 50% (1/2) | 0.0% (0/2) | 50% (1/2) | 0% (0/2) | 50.0% (1/2) | 50.0% (1/2) | 0.0% (0/2) | 50.0% (1/2) |
Colon cancer (n = 2) | 0.0% (0/2) | 50% (1/2) | 50.0% (1/2) | 50% (1/2) | 50% (1/2) | 50.0% (1/2) | 50.0% (1/2) | 0.0% (0/2) | 50.0% (1/2) | 50.0% (1/2) |